PFIZER NORVASC CONTINUES STRONG GROWTH WITH U.S. SALES OF $785 MIL., UP 51% FOR 1996: JAMA STUDY SAYS CALCIUM CHANNEL BLOCKERS "OVERUSED" IN ELDERLY MI SURVIVORS
Executive Summary
Pfizer's Norvasc continues to show strong growth in the U.S., with fourth quarter sales jumping 53% to $227 mil., the company reported.